Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 31.00
+3.90 (14.39%)
Jun 23, 2026, 3:04 PM CST
Hubei Goto Biopharm Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 606.18 | 532.57 | 565.5 | 604.4 | 588.37 |
Other Revenue | - | 4.03 | 0.9 | 0.17 | 2.52 |
| 606.18 | 536.6 | 566.4 | 604.57 | 590.89 | |
Revenue Growth (YoY) | 12.97% | -5.26% | -6.31% | 2.32% | 26.23% |
Cost of Revenue | 522.68 | 435.71 | 450.29 | 466.77 | 446.63 |
Gross Profit | 83.5 | 100.89 | 116.11 | 137.81 | 144.26 |
Selling, General & Admin | 65.64 | 67.29 | 50.16 | 42.5 | 40.58 |
Research & Development | 69.85 | 51.08 | 38.1 | 45.15 | 37.12 |
Other Operating Expenses | -18.42 | -6.98 | -3.53 | -0.17 | 1.53 |
Operating Expenses | 117.08 | 115.62 | 89.17 | 92.35 | 79.78 |
Operating Income | -33.58 | -14.73 | 26.93 | 45.46 | 64.48 |
Interest Expense | - | -23.52 | -13.18 | -13.68 | -5.17 |
Interest & Investment Income | - | 1.05 | 2.39 | 1.92 | 1.19 |
Currency Exchange Gain (Loss) | - | 1.12 | 1.05 | 2.24 | -0.6 |
Other Non Operating Income (Expenses) | -59.37 | -1.41 | -0.5 | -0.59 | -0.72 |
EBT Excluding Unusual Items | -92.95 | -37.48 | 16.7 | 35.35 | 59.17 |
Gain (Loss) on Sale of Investments | -0.27 | -0.35 | -0.01 | -0.18 | -1.05 |
Gain (Loss) on Sale of Assets | -1.44 | 0.11 | 0.17 | -0.01 | - |
Asset Writedown | -10.56 | -10.46 | -2.23 | -0.96 | -0.06 |
Legal Settlements | - | - | -0.03 | -0.05 | 0.01 |
Other Unusual Items | - | 2.64 | 4.53 | 4.36 | 28.05 |
Pretax Income | -105.21 | -45.54 | 19.12 | 38.51 | 86.12 |
Income Tax Expense | -23.49 | -13.88 | -2.17 | -1 | 8.05 |
Earnings From Continuing Operations | -81.73 | -31.66 | 21.29 | 39.51 | 78.07 |
Minority Interest in Earnings | 8.37 | 4.07 | 1.72 | 0.69 | 0.26 |
Net Income | -73.36 | -27.59 | 23.01 | 40.21 | 78.33 |
Net Income to Common | -73.36 | -27.59 | 23.01 | 40.21 | 78.33 |
Net Income Growth | - | - | -42.78% | -48.67% | 46.99% |
Shares Outstanding (Basic) | 115 | 115 | 115 | 115 | 106 |
Shares Outstanding (Diluted) | 115 | 115 | 115 | 115 | 106 |
Shares Change (YoY) | -0.29% | -0.05% | 0.13% | 8.77% | 22.87% |
EPS (Basic) | -0.64 | -0.24 | 0.20 | 0.35 | 0.74 |
EPS (Diluted) | -0.64 | -0.24 | 0.20 | 0.35 | 0.74 |
EPS Growth | - | - | -42.86% | -52.81% | 19.63% |
Free Cash Flow | -125.29 | -332.2 | -341.12 | -431.98 | -32.91 |
Free Cash Flow Per Share | -1.09 | -2.89 | -2.97 | -3.76 | -0.31 |
Dividend Per Share | - | - | 0.016 | - | 0.136 |
Gross Margin | 13.77% | 18.80% | 20.50% | 22.79% | 24.41% |
Operating Margin | -5.54% | -2.74% | 4.75% | 7.52% | 10.91% |
Profit Margin | -12.10% | -5.14% | 4.06% | 6.65% | 13.26% |
Free Cash Flow Margin | -20.67% | -61.91% | -60.23% | -71.45% | -5.57% |
EBITDA | 81.78 | 28.26 | 53.4 | 69.76 | 86.76 |
EBITDA Margin | 13.49% | 5.27% | 9.43% | 11.54% | 14.68% |
D&A For EBITDA | 115.36 | 42.98 | 26.47 | 24.3 | 22.28 |
EBIT | -33.58 | -14.73 | 26.93 | 45.46 | 64.48 |
EBIT Margin | -5.54% | -2.74% | 4.75% | 7.52% | 10.91% |
Effective Tax Rate | - | - | - | - | 9.35% |
Revenue as Reported | - | 536.6 | 566.4 | 604.57 | 590.89 |